Silvant Capital Management LLC
Position in HALO — Halozyme Therapeutics, Inc.
CIK 1738728
ATLANTA, GA
Position in HALO
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$56,354
New position
Shares Held
720
first reported quarter
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#530
of 664 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 100%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Silvant Capital Management LLC holds $7,835,576 across 9 Biotechnology names. HALO ranks #4 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
18,126 | $5,456,469 | |
| 2 | INSM |
INSMED Inc
|
19,761 | $2,106,917 | |
| 3 | AXSM |
Axsome Therapeutics, Inc.
|
270 | $66,087 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
This page
|
720 | $56,354 | |
| 5 | IONS |
Ionis Pharmaceuticals Inc
|
540 | $42,816 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
220 | $41,201 | |
| 7 | KRYS |
Krystal Biotech, Inc.
|
80 | $29,733 | |
| 8 | BBIO |
BridgeBio Pharma, Inc.
|
378 | $28,153 |
All Filings in HALO
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $56,354 | 720 | Shares | Other | 2026-08-11 | |
| No filing history on record for this holder in this stock. | ||||||